Skip to content

Immunome IMNM Free cash flow margin

Free cash flow margin at other companies

Pfizer logo
PfizerPFE
18%+8.8pp
Arcus Biosciences logo
Arcus BiosciencesRCUS
-207.2%
Nuvation Bio logo
Nuvation BioNUVB
-93.5%-45.2pp
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
-3,592%-4,290pp
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-212%-95.8pp
Exelixis logo
ExelixisEXEL
38.6%+2.9pp

Other financials

Income statement

See full
Revenue--100%
Operating income-$59.3M-32.9%
Net income-$53.8M-29.3%
EPS (diluted)-$0.48+7.7%

Balance sheet

See full
Cash & equivalents$582.7M+126%
Total debt$3.7M-22.6%
Total equity$588.7M+91.7%
Total assets$619.8M+80.9%

Cash flow

See full
Operating cash flow-$58.6M-10.5%
CapEx$3.0M-18.1%
Free cash flow-$61.6M-8.7%

Valuation

See full
Market cap$2.19B+323%
Enterprise value$1.61B+470%
P/S545.2×+498×

Profitability

See full
Operating margin-5,947.9%-12,002pp
Net margin-5,593.8%-11,284pp

Returns & leverage

See full
Return on equity-50.1%-10.8pp
Debt / equity0.0×
Current ratio21.7×+11.2×

Where this comes from

Calculated from Immunome’s reported figures.

Based on trailing twelve months.

The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunome's free cash flow margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immunome's free cash flow margin?
Immunome (IMNM) reported free cash flow margin of -5,118.9% in Q1 2026.
How has Immunome's free cash flow margin changed year-over-year?
Immunome's free cash flow margin decreased by 247.0% year-over-year, from -1,475.2% to -5,118.9%.
What does free cash flow margin mean?
Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.